Pacira BioSciences PCRX announced results from a pilot study evaluating the unique therapeutic approach of its iovera system compared to radiofrequency ablation (RFA) for chronic low back pain (CLBP).
BRISBANE, Calif. - Pacira BioSciences, Inc. (NASDAQ:PCRX) announced results from a randomized 30-patient pilot study showing its iovera° cryoneurolysis treatment demonstrated better outcomes than ...
“My colleagues and I agreed it was important to include Laparoscopic Radiofrequency Ablation of Fibroids in the release of Patient Information Sheets. It is vital for women to understand the options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback